Intratumoral Delivery of Genetically Engineered Anti-IL-6 Trans-signaling Therapeutics
-
Published:2024-07-09
Issue:
Volume:
Page:
-
ISSN:1073-6085
-
Container-title:Molecular Biotechnology
-
language:en
-
Short-container-title:Mol Biotechnol
Author:
Bento Raphaela, Scheller Jürgen, Parekkadan BijuORCID
Abstract
AbstractInterleukin-6 (IL-6) is a highly pro-inflammatory cytokine involved in the etiopathology of several inflammatory diseases and cancer. As so, the inhibition of IL-6 signaling pathways has emerged as an attractive therapeutic avenue for the treatment of several chronic diseases. Since IL-6 trans-signaling was described as the pathological branch of IL-6, selective inhibitors were developed. Next-generation variants with increased trans-signaling specificity and potency emerged as great candidates for the treatment of several diseases, with reduced off-target effects. The highly time-consuming and costly processes involving recombinant protein production, however, have hampered the progress of anti-cytokine pharmaceuticals in clinic so far. Herein, we developed gene therapeutic modalities of IL-6-trans-signaling inhibitors as alternatives for sustained recombinant protein secretion. By using an IL-6-dependent lymphoma cell line and xenograft tumor model, we demonstrated the superior inhibitory potential of second-generation anti-IL-6 trans-signaling therapeutic. We compared the efficiency of distinct gene delivery modalities using a bioluminescent biomarker probe and observed consistent protein production via cell-based delivery. When delivered intratumorally, genetically engineered sgp130FlyRFc-secreting cells significantly reduced tumor burden and increased animal survival, representing a promising therapeutic avenue to be explored in clinically relevant gene delivery applications.
Funder
National Institute of Biomedical Imaging and Bioengineering
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Schumertl, T., Lokau, J., Rose-John, S., & Garbers, C. (2022). Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochimica et Biophysica Acta, Molecular Cell Research, 1869(1), 119143. 2. Rose-John, S. (2021). Therapeutic targeting of IL-6 trans-signaling. Cytokine, 144, 155577. 3. Riethmueller, S., Somasundaram, P., Ehlers, J. C., Hung, C. W., Flynn, C. M., Lokau, J., Agthe, M., Düsterhöft, S., Zhu, Y., Grötzinger, J., & Lorenzen, I. (2017). Proteolytic origin of the soluble human IL-6R in vivo and a decisive role of N-glycosylation. PLoS Biology, 15(1), e2000080. 4. Lust, J. A., Donovan, K. A., Kline, M. P., Greipp, P. R., Kyle, R. A., & Maihle, N. J. (1992). Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine, 4(2), 96–100. 5. Rose-John, S., Jenkins, B. J., Garbers, C., Moll, J. M., & Scheller, J. (2023). Targeting IL-6 trans-signalling: past, present and future prospects. Nature Reviews Immunology, 23, 666–681.
|
|